Rehydrated lyophilized rifampicin-loaded mPEG-DSPE formulations for nebulization.
Rifampicin-loaded nanoparticles were prepared using two different molecular weights of poly-(ethylene oxide)-block-distearoyl phosphatidyl-ethanolamine (mPEG2000-DSPE and mPEG5000-DSPE) polymers. Particle sizes of all formulations studied were in the range of 162-395 nm. The entrapment efficiency (EE) was not affected by the copolymer's molecular weight, and the highest EE (100%) was obtained with drug to copolymer ratio of 1:5. The differential scanning calorimetry (DSC) thermograms showed Tg of rifampicin-loaded PEG-DSPE nanoparticles that shifted to a lower value, indicating entrapment of rifampicin in polymer matrix. The Fourier transformed infrared spectra revealed no chemical interactions between the drug and both copolymers. The in vitro drug release from the formulations occurred over 3 days and followed first-order release kinetic and Higuchi diffusion model. The nebulization of rehydrated lyophilized rifampicin mPEG-DSPE formulations had mass median aerodynamic diameter of 2.6 microm and fine particle fraction of 42%. The aerodynamic characteristic of the preparations was not influenced by the molecular weight of the copolymers. Therefore, it is suggested that both mPEG-DSPE are promising candidates as rifampicin carrier for pulmonary delivery.
Abdulla
Juma Masoud Abdulla
JM
Institute of Health, Sebha University, Sebha, Libya.
Tan
Yvonne Tze-Fung
YT
Darwis
Yusrida
Y
D000336:Aerosols / Q000138:chemical synthesis*; D000904:Antibiotics, Antitubercular / Q000737:chemistry; D003080:Cold Temperature; D004337:Drug Carriers / Q000138:chemical synthesis*; D004339:Drug Compounding / Q000379:methods; D004353:Drug Evaluation, Preclinical; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D010714:Phosphatidylethanolamines / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000737:chemistry*; D012293:Rifampin / Q000737:chemistry*; D014618:Vacuum; D014867:Water / Q000737:chemistry*
C519184:1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000); D000336:Aerosols; D000904:Antibiotics, Antitubercular; D004337:Drug Carriers; D010714:Phosphatidylethanolamines; D014867:Water; D011092:Polyethylene Glycols; D012293:Rifampin
Chest. 1997 May;111(5):1168-73
9149565
Eur J Pharm Biopharm. 1999 Sep;48(2):101-11
10469928
Int J Pharm. 2001 Oct 9;228(1-2):53-67
11576768
J Control Release. 1998 Jan 23;51(1):13-22
9685900
Adv Drug Deliv Rev. 2008 May 22;60(8):863-75
18308418
Int J Pharm. 2001 Jul 31;223(1-2):15-27
11451628
Int J Antimicrob Agents. 2001 Sep;18(3):245-52
11673037
J Control Release. 2003 Aug 28;91(1-2):97-102
12932641
Biomaterials. 2002 Nov;23(22):4425-33
12219833
Int J Pharm. 2007 Feb 22;331(1):1-10
17110063
Adv Drug Deliv Rev. 2002 Feb 21;54(2):169-90
11897144
Int J Pharm. 2001 Mar 14;215(1-2):113-21
11250097
Biomaterials. 2003 Jun;24(13):2395-404
12699677
J Microencapsul. 1998 Jan-Feb;15(1):1-19
9463803
Eur J Pharm Sci. 2004 Jun;22(2-3):127-44
15158898
Pharm Res. 2000 Aug;17(8):955-61
11028941
J Control Release. 2005 Feb 2;102(2):373-81
15653158
Trends Biotechnol. 2007 Dec;25(12):563-70
17997181
J Control Release. 2004 Mar 5;95(2):239-48
14980772
Pulm Pharmacol Ther. 2005;18(2):151-3
15649857
Int J Pharm. 2004 Jan 9;269(1):37-49
14698575
FEBS Lett. 1994 Oct 10;353(1):71-4
7926026
Int J Pharm. 2001 Oct 9;228(1-2):5-17
11576764
Respir Care. 2000 Jun;45(6):652-66
10894458
Biomaterials. 2005 Nov;26(33):6736-42
15935469
J Antimicrob Chemother. 2001 Sep;48(3):431-4
11533012
Int J Pharm. 2002 Jan 1;231(1):97-106
11719018
Int J Pharm. 2007 Apr 4;334(1-2):71-7
17113732
J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):3095-101
17048523